Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices
Author:
Open Access
- 11 April 2006
- journal article
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 174 (8) , 1120-1121
Abstract
Most new drugs that reach the market do not offer any significant therapeutic gain over existing products.[1][1],[2][2] Critics of the pharmaceutical industry have argued that these “me-too” drugs are a needless waste of resources. It can take hundreds of millions of dollars to develop them andKeywords
This publication has 4 references indexed in Scilit:
- “Me-Too” Products — Friend or Foe?New England Journal of Medicine, 2004
- Pharmaceutical Pricing in a Regulated MarketReview of Economics and Statistics, 2003
- Strategic Pricing of New PharmaceuticalsReview of Economics and Statistics, 1998
- Price and Quality Competition in the United States Drug IndustryThe Journal of Industrial Economics, 1978